In December, AMP started new positions in Regulus Therapeutics, Protagonist Therapeutics, SC Pharmaceuticals. AMP also added to it's Nabriva Therapeutics and Cidara Therapeutics positions. Further, AMP trimmed more of its Nektar Therapeutics position taking a profit of more than $30K in hypothetical gains (NKTR was up 280% at the time of sale).